MICAT

TECHATLAS
A DIVISION OF RACAPITAL

BRAF MUTANT ONLY

ARM1 — MEK+ BRAF ★ standard of care

BRAFi+MEK — Patient Group: A B C D

Demonstrate known effect of BRAF/MEKi combo as reference for other arms — PEP: mPFS: ≥12mo. SEP: ORR: 65% G 3/4: AE <40%

ACCEPTS ALL BRAF MUTANT PATIENTS WHO HAVE NOT ALREADY BEEN TREATED WITH BRAF INHIBITORS

CLASS
- MEK+BRAF

ARM2 — Novel Therapeutic for BRAF Mutant Patients

Novel BRAF targeted therapies — Patient Group: A B C D

Investigate efficacy of new BRAF targeted treatment — PEP: mPFS: ≥15mo. SEP: ORR: 80% G 3/4: AE <40%

ACCEPTS BRAF MUTANT PATIENTS WHO HAVE NOT ALREADY BEEN TREATED WITH BRAF INHIBITOR

CLASS
- Next-generation pan-BRAF inhibitors
- ERK inhibitors
- BRAFi + MEKi + PD(L)1
- CDK4/6 inhibitors available for combination study with BRAFi or MEKi

BRAF AGNOSTIC: ARMS BALANCED FOR BRAF MUTATIONAL STATUS AND OTHER FACTORS

ARM3 — Physician's Choice ★ standard of care

Physician's choice — Patient Group: A B C D

Demonstrate the known effects of standard of care — PEP: mPFS: ≥12mo. SEP: ORR: 55% G 3/4: AE <60%

ACCEPTS ALL PATIENTS

CLASS
- Chemotherapy
- CTLA4
- PD1

OR

ARM4 — PD1+ CTLA4 ★

PD1+CTLA4 — Patient Group: A B C D

Demonstrate the known effects of the PD1 + CTLA4 combo — PEP: mPFS: ≥12mo. SEP: ORR: 55% G 3/4: AE <60%

ACCEPTS PATIENTS OF ANY MUTATIONAL STATUS WHO HAVE NOT ALREADY RECEIVED PD1+CTLA4 THERAPY

CLASS
- PD1+CTLA4

ARM5 — PD(L)1+ Activator of Immune Response

PD1 + Activator of Immune Response — Patient Group: A B C D

Investigate efficacy of activators of immune response — PEP: mPFS: ≥15mo. SEP: ORR: 55% G 3/4: AE <60%

ACCEPTS ALL PATIENTS

CLASS
- Generate CTL response de novo
- Oncolytic virus
- Next-generation IL-2
- HDACi
- Off-the-shelf antigen vaccine
- IL-15
- Interferon-α

ARM6 — PD(L)1+ Second Generation Checkpoint Inhibitor

PD1 + Second Generation Checkpoint Inhibitor — Patient Group: A B C D

Investigate efficacy of second generation checkpoint inhibitors — PEP: mPFS: ≥15mo. SEP: ORR: 55% G 3/4: AE <40%

ACCEPTS ALL PATIENTS

CLASS
- IDO inhibitors
- CSFR1
- OX40
- Galectin
- KIR
- CEA-CAM1
- CD27
- GITR
- LAG-3
- 4-1BB
- B7-H3

NEXT STEPS FOR THERAPEUTICS

Treatments "graduating" from MICAT are recommended for advancement for Phase III evaluation. Each recommendation includes biomarker characterization.

New treatment arms are added.

Treatments arms that do not extend progression free survival will be halted after dosing a minimum number of patients, reducing patient and systemic burden

NEXT STEPS FOR PATIENTS

Biomarker signatures from all patients will be monitored and correlated with clinical endpoints and response patterns

Patients whose disease progresses will be eligible for re-randomization onto MICAT; they will have an increased chance of being allocated to a better performing treatment arm.

LEGEND

Patient Group		PEP	Primary endpoint
Treatment		SEP	Secondary endpoint
Purpose		mPFS	median progression free survival
Entry criteria for therapeutic		G 3/4 AE	Grade 3/4 adverse event
		ORR	Overall response rate

MUTATIONAL STATUS

BRAF WT			BRAF mutant		
PATIENT GROUP	TARGET	NAME OF DRUG	PATIENT GROUP	TARGET	NAME OF DRUG
A	PD1	pembrolizumab nivolumab	C	PD1	pembrolizumab nivolumab
B	PD1+CTLA4	nivolumab + ipilimumab	D	PD1+CTLA4	nivolumab + ipilimumab